Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

ences.  Key hormones, including adiponectin and leptin, also showed changes characteristic of non-PWS obese patients, demonstrating that the drug was highly active in these patients and had a similar effect to that seen in non-PWS patients.

"These results are very exciting for the treatment of PWS, as most patients showed improvements in body weight, hunger-related behaviors, and body fat content, despite the increased food intake included in the trial design," explained Dr. Jennifer Miller, Associate Professor of Pediatric Endocrinology, University of Florida, and Principal Investigator for the study.  "PWS is a complex genetic disease that is difficult to treat and the results of this trial demonstrate that beloranib has a beneficial impact on this underserved patient population.  Notably, we were encouraged by reports of fullness, a first-time occurrence for PWS patients who otherwise lack the capacity to feel sated after meals."

"PWS patients remain severely impacted by their disease and are not treatable with other anti-obesity agents," added Janalee Heinemann, Director of Research & Medical Affairs for the Prader-Willi Syndrome Association (USA).  "PWS represents one of the most severe forms of genetic obesity and we welcome these results, which are a significant step towards finding a treatment for those suffering from this life threatening condition."

Beloranib, a novel obesity therapy that utilizes a unique mechanism of action, is being studied for its ability to reduce body weight and improve cardiometabolic risk factors in obese patients with and without PWS.  This study was a randomized, double-blind, placebo-controlled trial to evaluate the safety and tolerability of a dose range of beloranib administered as twice-weekly subcutaneous injections for four weeks.  The randomized treatment part of the study was follow
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  Array BioPharma Inc. (NASDAQ: ... fourth quarter and full year of its fiscal ... Squarer, Chief Executive Officer of Array, noted, "Binimetinib and ... are on track for regulatory submissions in 2016. ... melanoma and BRAF-mutant colorectal cancer further validate the ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 /PRNewswire/ ... primary and secondary endpoints in a phase III study ... in adult patients with chronic non-cancer pain. Naldemedine is ... This is the third Phase III trial in which ... Study results showed that a 0.2 mg tablet ...
(Date:8/3/2015)... ST. PAUL, Minn. , Aug. 3, 2015 /PRNewswire/ ... devices using neuroblocking therapy to treat obesity, metabolic diseases ... C. McDougal has been appointed to the Board ... serve as a Class II Director until the 2018 ... qualified. Ms. McDougal has served in an ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
... of Novel Proteasome Inhibitor in ... Patients with Relapsed Solid Tumors, SOUTH SAN ... South Texas Accelerated Research Therapeutics (START),today announced the enrollment of ... Proteolix,s investigational drug, carfilzomib (PR-171).,START is participating in the study ...
... Protects the Ocular Surface Following Exposure to ... Dry Eye Symptoms, LAGUNA HILLS, Calif., Oct. 9 ... ALTY-0501, demonstrated statistically,significant advantages over vehicle in its ability ... Phase 2 study. The Phase 2 study utilized ...
Cached Medicine Technology:Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors 2Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors 3Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 2Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 3
(Date:8/3/2015)... Salt Lake City, UT (PRWEB) , ... August 03, 2015 , ... ... announced the release of the T500 cable , a Bluetooth Code Reader accessory ... mobile devices, including iOS products. The T500 helps enable a variety of barcode ...
(Date:8/3/2015)... , ... August 03, 2015 , ... According to an opinion piece published ... person’s diet leads to one pound of weight loss may not be accurate. While this ... translates to one pound of fat varies – based both on the individual and at ...
(Date:8/3/2015)... Los Angeles, California (PRWEB) , ... August 03, ... ... the Fifth Circuit Court of Appeals ruled in favor of the firm’s client ... Act ), North Cypress Medical Center must reimburse benefits for Hamsher’s residential treatment ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
Breaking Medicine News(10 mins):Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... Maik Behrens, Susann Foerster, Frauke Staehler, Jan-Dirk Raguse, and ... taste receptors are there to protect us from toxins, ... been debated whether we can discriminate between bitter-tasting compounds ... taste is encoded by a family of 25 TAS2 ...
... 13 AMERIGROUP,Corporation (NYSE: AGP ) today announced ... Investor Conference on November 27 in New,York City. ... Tuesday,November 27 at 2:00 p.m. Eastern Time, can be ... investors, page. A replay will be,available for 30 days, ...
... and Funds to Fight Homelessness in Los Angeles ... ANGELES, Nov. 13 United Way of Greater Los ... fight homelessness on,Saturday morning, November 17, 2007, by participating ... Park near downtown Los Angeles.,HomeWalk will engage participants through ...
... has chosen Rita B. Effros of the University of California, ... Kleemeier Award. This distinction is given annually to a GSA ... gerontology. , The award presentation will take place at GSA,s ... 16th - 20th, 2007 in San Francisco, CA. The actual ...
... Society of America (GSA) has chosen Lynn M. Martire ... of the Margret M. & Paul B. Baltes Foundation ... career contributions in behavioral and social gerontology. , The ... Scientific Meeting, which will be held from November 16th ...
... Nov. 13 Green Earth Waterless Carwash, the,only Los ... products and auto detailing services, today announced an agreement,with ... month as part of,the hospital,s employee appreciation program. An ... to the hospital. "We originally signed on for ...
Cached Medicine News:Health News:News Tips from the Journal of Neuroscience 2Health News:News Tips from the Journal of Neuroscience 3Health News:United Way of Greater Los Angeles and Fannie Mae Foundation Announce 3000 Marchers for HomeWalk 2007 2Health News:United Way of Greater Los Angeles and Fannie Mae Foundation Announce 3000 Marchers for HomeWalk 2007 3Health News:Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash 2
Double cuff electronic tourniquet....
... Safety. Convenience. Reliability. Cost. These are ... OR personnel, and administrators. With a special ... most practical elements of todays technology to ... , The A.T.S. 2000 Tourniquet uses ambient ...
... a revolutionary new addition to the Hall® ... PowerPro Battery System is the first and ... on the market. It is a full-function ... the requirements of large bone, small bone, ...
Stryker Instruments, the leader in cordless power, advances orthopaedics with the power, speed, versatility, reliability and performance through its heavy duty powered instruments....
Medicine Products: